Sirnaomics Ltd. (HKG:2257)

Market Cap	544.49M +49.5%
Revenue (ttm)	n/a
Net Income	-112.10M
EPS	-1.19
Shares Out	108.90M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,200
Open	5.00
Previous Close	5.00
Day's Range	4.90 - 5.00
52-Week Range	3.76 - 22.78
Beta	-0.04
Analysts	Strong Buy
Price Target	72.10 (+1,342.0%)
Earnings Date	Aug 28, 2026

About Sirnaomics

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs in the People’s Republic of China. The company’s therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates comprising STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; STP369 to treat head and neck cancer; and STP707 and STP355 to treat solid tumo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 37
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2257

Financial Performance

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error